Management of leptomeningeal malignancy

Bibliography

• EBERTH CJ: Zur entwicklung des epitheliomas dur pia under der lungs. Virchow's Arch. (1870) 49:51–63.
   Google Scholar
• GROSSMAN SA, KRABAK US. Leptomeningeal carcinomatosis. Cancer Treat. Rev. (1999) 25:103–109.
   PubMed Web of Science ®Google Scholar
• HILDEBRAND J, AOUN M: Chronic meningitis: still a diagnostic challenge. J. Neurol (2003) 250:653–660.
   PubMedGoogle Scholar
• FREEMAN M, BOYETT JM, GLICKSMAN AS et al.: Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: a ten year follow-up. Med. Pediatr. Oncol (1997) 28:98–107.
   PubMedGoogle Scholar
• HERMAN TS, HAMMOND N, JONES SE et al.: Involvement of the central nervous system by non-Hodgkin's lymphoma: the Southwest Oncology Group Experience. Cancer (1979) 43:390–397.
   PubMed Web of Science ®Google Scholar
• WASSERSTROM WR, GLASS JP, POSNER JB: Diagnosis and treatment of leptomeningeal metastases from solid tumours: experience with 90 patients. Cancer (1982) 49:759–772.
   PubMed Web of Science ®Google Scholar
• •A concise paper providing clear definitions of pathogenetic mechanisms and therapeutic limitations; modern despite its publication year.
   Google Scholar
• VAN DER REE TC, DIPPEL DW, AVEZAAT CJ et al.: Leptomeningeal metastasis after surgical resection of brain metastases. J. Neurol Neurosurg. Psychiatry (1999) 66:225–227.
   Google Scholar
• CRIVELARI D, PAGANI O, VERONESI A et al.: High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann. Oncol (2001) 12:353–356.
   PubMedGoogle Scholar
• BENDELL JC, DOMCHEK SM, BURNSTEIN HJ et al.: Central nervous system metastases in women who receive tratuzumab-based therapy for metastatic breast carcinoma. Cancer (2003) 97:2972–2977.
   PubMed Web of Science ®Google Scholar
• KOKKORIS CP: Leptomeningeal carcinomatosis. How does cancer reach the pia-arachnoid? Cancer (1983) 51:154–160.
   Google Scholar
• DIMOPOULOS A: Leptomeningeal metastases. Curr. Neurol Neurosci. Rep. (2004) 4(3):196–204.
   PubMedGoogle Scholar
• PAVLIDIS N: The diagnostic and therapeutic management of leptomeningeal carcinomatosis. Ann. Oncol (2004) 15\(Suppl. 4):285–291.
   Google Scholar
• CHAMBERLAIN MC, KORMANIK PA, GLANTZ MJ: A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases. Neuro. Oncol (2001) 3:42–45.
   PubMed Web of Science ®Google Scholar
• COLLIE DA, BRUSH JP, LAMMIE GA et al.: Imaging features of leptomeningeal metastases. Clin. Radiol. (1999) 54:765–771.
   PubMed Web of Science ®Google Scholar
• HUSTO HO, AUR RJ, VERZOSA MS et al.: Prevention of central nervous system leukemia by irradiation. Cancer (1973) 32:585–597.
   PubMedGoogle Scholar
• SAUSE WT, CROWLEY J, EYRE HJ et al.: Whole brain irradiation and intrathecal methotrexate in the treatment of solid tumour leptomeningeal metastases-a Southwest Oncology Group study./ Neuro-Oncol (1988) 6:107–112.
   PubMedGoogle Scholar
• BOOGERD W, VAN DEN BENT MJ, KOEHLER PJ et al.: The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur. j Cancer (2004) 40:2726-2733. The one and only prospective randomised trial to evaluate the role of intrathecal therapy in LC.
   Google Scholar
• BLEYER WA: Intrathecal depot cytarabinetherapy: a welcome additon to a limited armamentarium. Clin. Cancer Res. (1999) 5:3349–3351.
   PubMedGoogle Scholar
• TSUCHIYA J, MOTEKI M, SHIMANO S et al.: Proliferation kinetics of the leukemic cells in meningeal leukemia. Cancer (1978) 42:1255–1262.
   PubMedGoogle Scholar
• LISHNER M, PERRIN RG, FELD R et al.: Complications associated with Ommaya reservoirs in patients with cancer. Arch. Int. Med. (1990) 150:173–176.
   PubMedGoogle Scholar
• ZIMM S, COLLINS JM, MISER J et al.:1-13-D-Arabinofuranosylcytosine cerebrospinal fluid kinetics. Clin. Pharmacol Ther. (1984) 35:826–830.
   PubMed Web of Science ®Google Scholar
• BLEYER WA: Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat. Rev. (1977) 4:87–101.
   PubMed Web of Science ®Google Scholar
• BERG SL, CHAMBERLAIN MC: Systemic chemotherapy, intrathecal chemotherapy and symptom management in the treatment of leptomeningeal metastasis. Curr. Oncol. Rep. (2003) 5:29–40.
   PubMedGoogle Scholar
• CHAMBERLAIN MC, KORMANIK P: Carcinomatous meningitis secondary to non small cell lung cancer: combined modality therapy. Arch. Neurol (1998) 55:506–512.
   PubMed Web of Science ®Google Scholar
• KIM DY, LEE KW, YUN T et ell.: Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumour: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn. J. Clin. Oncol (2003) 33(12):608–612.
   Google Scholar
• CHAMBERLAIN MC, KORMANIK PA: Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. Neurosurg (1997) 87:694–699.
   Google Scholar
• PFEFFER MR, WYGODA M, SIEGAL T: Leptomeningeal metastases-treatment results in 98 consecutive patients. /srae/J. Med. Sc./. (1988) 24:611–618.
   Google Scholar
• SIEGAL T, SANDBANK U, GABRIZON A et al.: Alteration of blood-brain-CSF barrier in experimental meningeal carcinomatosis: a morphologic and adriamycin-penetration study. J. Neuro-Oncol. (1987) 4:233–242.
   PubMedGoogle Scholar
• TETEF ML, MARGOLIN KA, DOROSHOW JH et al.: Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother. Pharmacol. (2000) 46:19–22.
   PubMed Web of Science ®Google Scholar
• CHAMBERLAIN MC, KORMANIK P, GLANTZ M: Recurrent primary central nervous system lymphoma complicated by lymphomatous meningitis. Oncol. Rep. (1998) 5:521–523.
   PubMed Web of Science ®Google Scholar
• GLANTZ MJ, COLE BF, RECHT L et al.: High-dose intravenous methotrexate for patients with non-leukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J. Clin. Oncol. (1998) 16:1561–1567.
   Google Scholar
• FRICK J, RITCH PS, HANSEN RN, ANDERSON T: Successful treatment of meningeal leukemia using systemic high-dose cytosine arabinoside. j Clin. Oncol. (1984) 2:365–368.
   PubMed Web of Science ®Google Scholar
• BLEYER W: Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat. Rep. (1981) 65\(Suppl. 1):89–98.
   Google Scholar
• MURRY DJ, BLANEY SM: Clinical pharmacology of encapsulated sustained-release cytarabine. Ann. Pharmacother. (2000) 34:1173–1178.
   PubMed Web of Science ®Google Scholar
• GLANTZ MJ, LAFOLLETTE S, JAECKLE KA et al.: Randomized trial of a slow release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J. Clin. Oncol. (1999) 17:3110–3116.
   PubMed Web of Science ®Google Scholar
• GLANTZ MJ, JAECKLE KA, CHAMBERLAIN MC et al.: A randomized controlled trial comparing intrathecal sustained-release cytarabine to intrathecal methotrexate in patients with neoplastic meningitis from solid tumours. Clin. Cancer Res. (1999) 5:3394–3402.
   PubMed Web of Science ®Google Scholar
• •A prospective randomised trial that established the benefit and convenience of liposomal intrathecal Ara-C over standard intrathecal methothrexate for patients with solid tumour LC.
   Google Scholar
• BLANEY S, COLE D, BALIS E et al.: Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in human primates. Cancer Res. (1993) 53:725–727.
   PubMed Web of Science ®Google Scholar
• BLANEY S, HEIDEMAN R, BERG S et al.: Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J. Clin. Oncol. (2003) 21:143–147.
   PubMed Web of Science ®Google Scholar
• SCHULZ H, PELS H, SCHMIDT-WOLF I, ZEELEN U, GERMING U, ENGERT A: Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica (2004) 89:753–754.
   PubMed Web of Science ®Google Scholar
• LAUFMAN LR, FORSTHOEFEL KF: Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin. Breast Cancer (2001) 2:235.
   PubMedGoogle Scholar
• FRIEDMAN HS: Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. Semin. Oncol. (2000) 27\(Suppl. 6):35–40.
   Google Scholar
• SIEGAL T, LOSSOS A, PFEFFER MR: Leptomeningeal metastasis: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology (1994) 44:1463–1469.
   PubMed Web of Science ®Google Scholar
• BOOGERD W, HART AA, VAN DER SANDE JJ, ENGELSMAN E: Meningeal carcinomatosis in breast cancer: prognostic factors and influence of treatment. Cancer (1991) 67:1685–1695.
   PubMed Web of Science ®Google Scholar